MiNK Therapeutics (NASDAQ:INKT) Stock Rated Buy in New Coverage at HC Wainwright

HC Wainwright initiated coverage on shares of MiNK Therapeutics (NASDAQ:INKT) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $38.00 target price on the stock. HC Wainwright also issued estimates for MiNK Therapeutics’ Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.58) EPS.

A number of other equities analysts have also recently weighed in on the company. Zacks Research cut MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Finally, B. Riley Financial restated a “buy” rating and set a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a research report on Wednesday, October 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MiNK Therapeutics presently has an average rating of “Hold” and a consensus price target of $44.00.

MiNK Therapeutics Price Performance

MiNK Therapeutics stock opened at $10.47 on Wednesday. The firm has a market cap of $53.42 million, a PE ratio of -4.36 and a beta of 0.49. The stock’s fifty day moving average price is $11.23 and its two-hundred day moving average price is $11.26. MiNK Therapeutics has a one year low of $8.48 and a one year high of $16.93.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02). Sell-side analysts expect that MiNK Therapeutics will post -2.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jennifer Buell sold 6,938 shares of the business’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the sale, the chief executive officer owned 74,195 shares of the company’s stock, valued at $783,499.20. The trade was a 8.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 20.40% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.